Tirzepatide

Last Updated: August 2026

Tirzepatide is a 39-amino-acid synthetic peptide and the first FDA-approved dual GIP/GLP-1 receptor agonist, approved as a prescription medicine for type 2 diabetes and for chronic weight management. It was approved for diabetes in May 2022 and for obesity in November 2023. Research-grade tirzepatide is also sold by third-party laboratories for laboratory use only — that material is not the FDA-approved prescription product and carries no pharmacy-grade quality controls. The compounded-tirzepatide era is over: the FDA declared the tirzepatide shortage resolved on December 19, 2024 (reaffirming its October 2024 determination after a court remand), and its enforcement-discretion window for compounders closed on February 18, 2025 (503A pharmacies) and March 19, 2025 (503B outsourcing facilities).1 source On April 30, 2026 the FDA proposed excluding tirzepatide (along with semaglutide and liraglutide) from the 503B bulks list after finding no clinical need for outsourcing facilities to compound them — a proposal still pending as of August 2026.1 source For athletes: tirzepatide is not on the WADA Prohibited List — like semaglutide, it is tracked under WADA's 2026 Monitoring Program, which is not a ban.1 source

What is tirzepatide and how does the dual GIP/GLP-1 mechanism work?

Tirzepatide activates both GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) receptors with a single 39-amino-acid molecule, producing larger insulin-sensitizing and weight-loss effects than GLP-1-only agonists. The dual mechanism increases insulin secretion glucose-dependently, slows gastric emptying, suppresses appetite via central GLP-1 pathways, and adds GIP-mediated effects on adipocyte function. The molecule is bound to a C20 fatty diacid side chain, extending half-life to approximately 5 days and enabling once-weekly subcutaneous dosing. Evidence level: Human RCT (multiple Phase 3 trials in SURPASS and SURMOUNT programs).

What does the Phase 3 evidence show for tirzepatide?

In SURMOUNT-1 (n=2,539), tirzepatide produced an average weight loss of 22.5% at the 15 mg dose over 72 weeks in adults with obesity without type 2 diabetes. Lower doses (5 mg, 10 mg) produced 16.0% and 21.4% weight loss respectively versus 2.4% for placebo.1 source In SURPASS trials for type 2 diabetes, tirzepatide reduced HbA1c by up to 2.4 percentage points and outperformed semaglutide head-to-head in SURPASS-2. For cross-compound context, see our semaglutide vs tirzepatide comparison guide. Evidence level: Human RCT (Phase 3).

How does tirzepatide compare to retatrutide and semaglutide?

Tirzepatide sits between semaglutide (single-receptor) and retatrutide (triple-receptor) on both mechanism complexity and weight-loss efficacy. Tirzepatide's 22.5% SURMOUNT-1 result exceeded semaglutide's 14.9% in STEP 1 The direct head-to-head SURMOUNT-5 trial (n=751) confirmed it in 2025: tirzepatide averaged 20.2% weight loss at 72 weeks versus 13.7% for semaglutide 2.4 mg.1 source retatrutide's TRIUMPH-4 result of 28.7% exceeded tirzepatide's retatrutide's published Phase 2 result (24.2% at 48 weeks) already approaches tirzepatide's Phase 3 figure, and its Phase 3 TRIUMPH program has reported larger reductions (~28–30%) in company topline announcements that are not yet peer-reviewed1 source, and retatrutide's TRIUMPH-4 result of 28.7% exceeded tirzepatide's. Tirzepatide is the only one of the three currently FDA-approved for obesity in the United States.

What are the documented side effects of tirzepatide?

The most common tirzepatide side effects in SURMOUNT-1 were gastrointestinal — per the US label's trial table, nausea (25–29% across the 5–15 mg doses vs 8% on placebo), diarrhea (19–23% vs 8%), constipation (11–17% vs 5%), and vomiting (8–13% vs 2%)1 source — typically mild-to-moderate and concentrated in the dose-escalation phase. Tirzepatide hair loss has emerged as a notable patient-reported side effect, characterized in the SURMOUNT data and analyzed in detail in our tirzepatide side effects guide. Discontinuation rates due to adverse events ranged from 4.3% to 7.1% across doses. Evidence level: Human RCT (Phase 3).

What is the regulatory status of tirzepatide?

Tirzepatide is FDA-approved for type 2 diabetes (May 2022) and for chronic weight management (November 2023), with EMA approval following for both indications. It is available by prescription through licensed pharmacies. Research-grade tirzepatide sold by third-party laboratories is not the FDA-approved prescription product — that material is supplied for research use only and does not carry pharmacy-grade quality controls. For the prescription-vs-research-grade legal distinction, see our peptide regulatory status by country guide.

Why does tirzepatide vendor verification matter even though it's FDA-approved?

Because the FDA approval applies to the brand owner's pharmacy-distributed prescription product — not to research-grade tirzepatide sold by third-party labs, which is a separate supply chain with its own quality risks. The active ingredient may be the same molecule, but research-grade material is subject to wider purity variance, occasional underdosing, and inconsistent endotoxin control. Independent HPLC purity testing and mass spectrometry identity confirmation (expected MW 4,813.5 Da) are the only meaningful purity signals a research-grade vendor can provide. Learn how to interpret these in our how-to-test-peptides hub and reading peptide lab test results guide.

How does Peptigrity verify tirzepatide vendors?

Peptigrity collects independent third-party Certificates of Analysis for tirzepatide from shops' official channels and verifies each for authenticity before publishing. Because shops choose which COAs to publish, results reflect the batches shops have made public rather than every production batch — a selection bias we state openly. A community-funded Testing Grant to purchase and test vials anonymously is in development. The lab test table above this section shows the full cross-shop dataset, sortable by date, purity, and labeled-vs-tested quantity. Tests are sourced from named labs including Freedom Diagnostics, Janoshik Analytical, Chromate, Vanguard Laboratory, and Trust Pointe Analytics. Our trust score methodology weights reviews (50%) and lab purity (50%) — full detail in how we calculate trust scores.

Frequently Asked Questions

How can I verify a tirzepatide vendor is selling real product?

The only reliable purity signal is an independent third-party HPLC certificate of analysis from a lab the vendor does not own or pay — not a vendor-published COA on vendor letterhead. Peptigrity publishes independent tirzepatide test results from independent labs in the table above. For COA interpretation, see red flags in peptide certificates of analysis.

Is research-grade tirzepatide legal to purchase?

Research-grade tirzepatide is legal to purchase as a research chemical for laboratory use in most jurisdictions, but it is not approved for human consumption and is not the FDA-approved prescription product. The FDA-approved version requires a prescription. For the legal distinction between research-grade and pharmacy-grade supply, see our peptide legal status guide.

Can I get tirzepatide from a compounding pharmacy?

Generally no — that pathway closed in early 2025. Mass compounding was lawful only during the shortage; the FDA declared the tirzepatide shortage resolved on December 19, 2024, and its enforcement-discretion window closed on February 18, 2025 for 503A pharmacies and March 19, 2025 for 503B outsourcing facilities.1 source In April 2026 the FDA additionally proposed excluding tirzepatide from the 503B bulks list, which would close the main remaining route permanently.1 source For the full sequence of events, see the FDA peptide regulation 2025–2026 timeline. When tirzepatide is on the FDA shortage list, 503A pharmacies may compound it; when off the list, that pathway closes. For the current state of compounding pharmacy access and FDA determinations, see FDA peptide regulation 2025–2026: the complete timeline.

Why does research-grade tirzepatide cost less than the pharmacy product?

Research-grade tirzepatide is manufactured by third-party laboratories without the pharmaceutical-grade overhead (FDA inspections, full GMP compliance, branded packaging, distribution chain markups) that prices the pharmacy product. It also doesn't carry the regulatory protection or quality guarantees those products do. Current research-grade market range is broken down in how much do peptides cost.

Does Peptigrity recommend a tirzepatide dose?

No. Peptigrity is an independent review platform, not a medical authority — and research-grade tirzepatide is not approved for human consumption. The doses studied in SURMOUNT and SURPASS (2.5 mg through 15 mg weekly, with mandatory titration) were administered under clinical supervision. Anyone considering tirzepatide should consult a licensed physician about the prescription product.

How does tirzepatide compare to retatrutide for weight loss?

Retatrutide has reported larger percent weight loss than tirzepatide, but the comparison is not yet settled science: retatrutide's published evidence is a Phase 2 trial (24.2% at 48 weeks), while its larger Phase 3 TRIUMPH figures (~28–30%) are company topline announcements, not yet peer-reviewed.1 source Tirzepatide's SURMOUNT-1 result was 22.5% at 72 weeks — and tirzepatide is FDA-approved while retatrutide is not.1 source No head-to-head Phase 3 data exists yet. Full mechanism breakdown is in our retatrutide triple-agonist science guide.

This section is for educational and informational purposes only and does not constitute medical advice. Research-grade tirzepatide sold for laboratory use is not the FDA-approved prescription product. Always consult a qualified healthcare provider before using any peptide or research compound. Peptigrity is an independent review platform and does not sell, endorse, or recommend specific products or vendors.